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Abstract
Context, objective: Growth hormone deficiency (GHD) is associated with insulin resistance and diabetes, in particular after
treatment in children and adults with pre-existing metabolic risk factors. Our aims were. i) to evaluate the effect on glucose
metabolism of rhGH treatment and withdrawal in not confirmed GHD adolescents at the achievement of adult height; ii) to
investigate the impact of GH receptor gene genomic deletion of exon 3 (d3GHR).
Design, setting: We performed a longitudinal study (1 year) in a tertiary care center.
Methods: 23 GHD adolescent were followed in the last year of rhGH treatment (T0), 6 (T6) and 12 (T12) months after rhGH
withdrawal with fasting and post-OGTT evaluations. 40 healthy adolescents were used as controls. HOMA-IR, HOMA%b,
insulinogenic (INS) and disposition (DI) indexes were calculated. GHR genotypes were determined by multiplex PCR.
Results: In the group as a whole, fasting insulin (p,0.05), HOMA-IR (p,0.05), insulin and glucose levels during OGTT
(p,0.01) progressively decreased from T0 to T12 becoming similar to controls. During rhGH, a compensatory insulin
secretion with a stable DI was recorded, and, then, HOMAb and INS decreased at T6 and T12 (p,0.05). By evaluating the
GHR genotype, nDel GHD showed a decrease from T0 to T12 in HOMA-IR, HOMAb, INS (p,0.05) and DI. Del GHD showed a
gradual increase in DI (p,0.05) and INS with a stable HOMA-IR and higher HDL-cholesterol (p,0.01).
Conclusions: In not confirmed GHD adolescents the fasting deterioration in glucose homeostasis during rhGH is
efficaciously coupled with a compensatory insulin secretion and activity at OGTT. The presence of at least one d3GHR allele
is associated with lower glucose levels and higher HOMA-b and DI after rhGH withdrawal. Screening for the d3GHR in the
pediatric age may help physicians to follow and phenotype GHD patients also by a metabolic point of view.
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Introduction
Growth hormone (GH) has pleiotropic functions in humans.
GH/insulin-like growth factor-1 (IGF-I) axis is the main regulator
of post-natal growth, but it has other main metabolic actions such
as the regulation of body composition, muscle and bone
metabolism. Furthermore, in the post-absorptive state, GH mainly
acts on stimulating lipolysis and lipid oxidation in order to switch
metabolism from glucose and protein to lipid utilization. At
present, it is reported that GH administration is followed by
lipolysis but also by insulin resistance and relatively sustained
hyperglycemia [1–3]. GH-induced lipolysis appears as the most
important determinant of GH anti-insulin actions, by inhibiting
insulin-stimulated glucose uptake especially in muscles [4,5].
Whether the impairment in peripheral insulin sensitivity is mainly
located in muscle and mostly due to higher disposable free fatty
acids, GH is also able to reduce hepatic insulin sensitivity in
healthy humans and to counterbalance the anti-lipolytic actions of
hyperinsulinemia [1,6]. Some of these effects are direct actions,
whereas others are IGF-I mediated [1].
Other mechanisms may be implicated on the metabolic effects
of GH, as the interaction of GH with the insulin receptor [7,8] and
the presence of several polymorphisms including the GH receptor
(GHR) exon 3 deletion (d3GHR) which seems to play a role in
glucose homeostasis in GHD subjects [9] and in general
population [10,11].
Several studies in adults have determined the effects of GH
replacement therapy on insulin sensitivity. Short-term rhGH
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e87157
therapy deteriorates insulin sensitivity with an improvement on
long-term in the majority but not in all studies. These conflicting
data are probably due to differences in sample size, methods of
evaluation of insulin sensitivity and doses of rhGH [1,12–15].
There are suggestions that rhGH therapy increases the risk of type
2 and/or secondary diabetes in GHD adults with pre-existing
metabolic risk factors [16]. Similarly, in children data from
registries show a slower increase in the incidence of diabetes due to
GH treatment in those patients with pre-existing risk factors
[17,18]. Despite this, a few data describe insulin secretion at final
height in the ‘‘so called’’ transition phase. Evidence to date
suggests an increase in insulin sensitivity after cessation of GH
treatment [19–21], but more studies are needed to clarify. In
particular, no attention has been paid on those subjects which
were not reconfirmed as GHD after stopping therapy.
Euglycemic hyper-insulinemic clamp is considered as the ‘‘gold
standard’’ for quantifying insulin sensitivity in vivo, but this
method is not applicable on a great population in daily clinical
practice. Insulinogenic index (INS) and disposition index (DI) are
new indirect methods for measure beta-cell function, using oral
glucose tolerance test (OGTT) -derived measures, and are early
markers of inadequate beta-cell or peripheral compensation. They
allow the investigation of a larger number of patients [22]. Recent
data indicate INS and DI as the best predictors of future type 2
diabetes in adults [23–25].
In order to understand the metabolic effects of rhGH therapy in
adolescents with unconfirmed GHD at the achievement of adult
height, we evaluated glucose metabolism in the last year of rhGH
replacement and in first year after rhGH discontinuation
compared with a healthy counterpart. Because some polymor-
phisms of the GHR could have a role in glucose metabolism and
insulin resistance, we also evaluated whether the d3GHR deletion
has a role on glucose homoeostasis during and after rhGH
withdrawal.
Methods
This was a single-center longitudinal study conducted at
Division of Pediatrics, University of Piemonte Orientale (Novara,
Italy). We consecutively recruited 35 GH-deficient (GHD) adoles-
cents at the end of puberty and in the last year of rhGH therapy
and 45 healthy age and sex matched adolescents. The recruitment
was opened from September 2006 to December 2011 The study
was approved by the Ethics Committee of Maggiore della Carita`
Hospital (Novara) and informed written consent was obtained
from all subjects and their parents before study. Patients were
eligible if they had an idiopathic isolated GHD at diagnosis, had
completed puberty (Tanner stage 4 and 5), the adult height was
almost achieved with a bone age similar to the chronologic age
and growth velocity near to 2 cm/year, and GHD was not
confirmed at retesting (GD, group 1). Patients with coexistent
other chronic or endocrine diseases, syndromes, diabetes, tumors
or drugs interfering with glucose metabolism were excluded.
Healthy control adolescents (CS, group 2) were eligible if they
were at the end of puberty, normal-weight, with no history of
organic or psychiatric diseases in particular no neurological,
endocrine, liver, and kidney abnormalities.
Study Design and Assays
GHD adolescents were evaluated at fasting for IGF-1, total- (T-
c), HDL- (HDL-c) cholesterol, triglycerides (TG), C-peptide and
with an OGTT (1.75 g of glucose solution per kg, maximum
75 gr) in the last year of rhGH therapy (T0), and at 6 (T6) and 12
months (T12) after therapy withdrawal. In the year after GH
discontinuation the retesting was performed with the GHRH plus
arginine test with the adoption of the transition cut-offs [26]. In
healthy adolescents the OGTT was performed at baseline.
Impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT) were defined according to American Diabetes Association
classifications as fasting plasma glucose of $100 to 125 mg/dl
nmol/l, and as 2-h post-OGTT glucose of $140 to 199 mg/dl,
respectively. Also the definition of diabetes was performed
according to the criteria of the American Diabetes Association
[27].
Blood samples during OGTT were drawn for the determination
of glucose and insulin every 30 min from 09 to 1209 min. The area
under curve (AUC) for plasma glucose and insulin were calculated
by the trapezoidal rule.
Insulin resistance was estimated, in the basal state, by use of the
homeostasis model assessment (HOMA-IR) = fasting glucose 6
fasting insulin/22.5; beta-cell function at fasting was calculated
using the formula of HOMA-b= (20 6 fasting insulin)/(fasting
glucose 23.5). Insulin sensitivity was calculated from the Matsuda
[10,000/!(fasting glucose 6 fasting insulin) 6 (Gm6Im)] and
QUICKI (1/log10 fasting insulin+log10 fasting glucose) indexes
[28].
The area under the curve (AUC) for parameters after OGTT
was calculated according to the trapezoidal rule. Delta glucose
(DG30–0) and insulin (DI30–0) were evaluated as the change in
glucose and insulin concentrations from 0 to 30 min. The stimulus
for insulin secretion in the increment in plasma glucose as
insulinogenic index was calculated as the ratio of the changes in
insulin and glucose concentration from 0 to 30 min (INS). Beta-
cell compensatory capacity was evaluated by the disposition index
defined as the product of the Matsuda Index and INS (DI) [29]. In
addition, each subgroup and all subjects together were divided into
four groups according to the 2-h glucose levels,: 1) less than
100 mg/dL, 2) 100–119 mg/dL, 3) 120–139 mg/dL 4) above
140 mg/dL according to the risk to have a lower DI [30].
Plasma glucose levels (mg/dl; 1 mg/dl:0,05551 mMol/liter)
were measured by the gluco-oxidase colorimetric method
(GLUCOFIX, by Menarini Diagnostici, Florence, Italy). Insulin
(mUI/ml; 1 mUI/ml= 7.175 pmol/l) was measured by chemilu-
minescent enzyme-labelled immunometric assay (Diagnostic
Products Corporation, Los Angeles, CA). Sensitivity: 2 mUI/ml.
Intra- and inter-assay CV ranges: 2.5–8.3 and 4.4–8.6%.
HbA1c levels were measured by the high-performance liquid
chromatography (HPLC), using a Variant machine (Biorad,
Hercules, CA); intra- and inter-assay coefficients of variation are
respectively lower than 0.6 and 1.6%. Linearity is excellent from
3.2% (11 mmol/mol) to 18.3% (177mmol/mol).
T-c (mg/dl; 1 mg/dl: 0.0259 mMol/l), HDL-c (mg/dl; 1 mg/
dl: 0.0259 mMol/l), TG (mg/dl; 1 mg/dl: 0.0113 mMol/l), and
C-peptide (ng/ml) were evaluated using standardized methods in
the hospital’s chemistry laboratory. Plasma T-c concentration was
measured by esterase and oxidase conversion (Advia 1650, Bayer
Diagnostics, Newbury, UK); coefficient of variation (CV) 1.9%.
Plasma TG and HDL-c concentrations were measured by
enzymatic determination (Advia 1650, Bayer Diagnostics, New-
bury, UK); CV 1.7%. LDL-c was calculated by Friedwald
mathematical for individuals with TG,150 mg/dl.
Serum IGF-I was measured by Liason automated chemilumi-
nescence analyzer supplied by DiaSorin with a measurement
range of 3–1500 ng/ml. Age and gender-reference ranges were
used to calculate an IGF1 SDS for each patient.
Disposition Index in GHD Adolescents
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Anthropometric Measurements
Height was measured by the Harpenden stadiometer and
weight by using electronic scale. Body mass index (BMI) was
calculated as body weight divided by squared height (kg/m2).
Height, weight and BMI were stratified according to Italian
growth charts [31]. Height velocity (HV) was calculated from the
difference of mean heights obtained from 2 consecutive visits,
divided by time between visits, and adjusted to a 12-month
interval. Waist circumference was measured with a soft tape,
midway between the lowest rib margin and the iliac crest, in the
standing position. Hip circumference was measured over the
widest part of the gluteal region, and the waist-to-hip ratio was
calculated. Systolic (SBP) and diastolic (DBP) blood pressure were
measured three times at the left arms by using a standard mercury
sphygmomanometer and the mean value was recorded and
stratified according to paediatric percentiles of National High
Blood Pressure Education Program Working Group on High
Blood Pressure in Children and Adolescents [32].
DNA Extraction and Genetic Analysis
At the end of the clinical protocol, after T12, genomic DNA was
isolated from peripheral blood leukocytes by standard methods.
The d3GHR polymorphism was detected as described previously
[33] based on a multiplex PCR assay with a combination of 3
primers (G1, G2 and G3) that specifically amplify the wild type
(935 base pairs bp) and the deleted (532 bp) alleles. Amplification
products were visualized by electrophoresis on a 1.5% agarose gel
stained with ethidium bromide (Figure S1).
Subjects with at least one copy of the exon-3 deleted GHR (d3/
d3 and fl/d3; Del) were grouped together for comparison with full-
length homozygote subjects (fl/fl; nDel).
Statistical Analysis
Data are expressed as mean6SEM. For continuous variables,
the variation between groups was compared by means on
nonparametric Wilcoxon, Mann-Whitney U, or chi-square tests,
where appropriate. Trends were assessed by nonparametric
Friedman test. A correlation analysis was performed using the
Pearson’s correlation test with a logarithmic transformation when
necessary.
Statistical significance was assumed for p,0.05. All statistical
analyses were performed with SPSS for Windows version 17.0
(SPSS INC; Chicago, IL, USA).
Results
GHD before and after GH Discontinuation
Of the 35 GHD enrolled subjects, 23 performed two OGTTs
and completed the study. Of the 45 CS, 5 subjects had discomfort
during OGTT and were excluded.
Clinical characteristics of CS and GHD at T0 and T12 are
reported in Table 1 and 2. GHD subjects had received GH
replacement therapy for 7.362.0 years. The last dose of GH was
12.060.5 mg/week. The GH peak at the Arginine+GHRH test
was of 72.065.6 ng/ml.
One GHD subject showed IFG at T0 and T6 and two subjects
IGT at T0. No glucose alterations were found at T12. The
distribution of post-OGTT 2hrs glucose levels at each time point
was reported in Table 2. HbA1c levels were 5.360.1%
(34.061.0 mmol/mol) in the last year of therapy. No differences
in waist, waist/hip ratio, BMI, SBP, DBP, LDL-c and TG were
shown in GHD among visits. T-c and HDL-c levels were lower at
T6 than T0, and HDL-c levels also at T12 than T0 in GHD
although the trend among visits was not significant (Table 2).
Basal glucose levels were similar among the 3 times. Fasting
insulin (p,0.05), HOMA-IR (p,0.05) insulin and glucose levels at
each time point after OGTT (p,0.01), DG0–30 (p,0.05) and DI0–
30, insulin mean and insulin AUC (p,0.01) progressively
decreased from T0 to T12. Conversely, C-peptide (p,0.0001),
Matsuda and QUICKI indexes increased from T0 to T12
(p,0.05). Despite higher insulin resistance during the last year
of GH treatment, a compensatory insulin secretion was recorded:
HOMA-b and INS were higher at T0, and progressively
decreased at T6 and T12 (p,0.05), with a stable DI. Also IGF1
levels and IGF-I SDS decreased from T0 to T12 (p,0.0001)
(Table 2).
A trend to decrease in DI across 2 h glucose groups (,100;
100–119; 120–139; .140 mg/dl) was observed and maintained at
each time point in GHD subjects; T0 (8.761.4; 7.261.1; 5.261.4;
3.260.8, respectively; p,0.01; x2 12.156), T6 (7.561; 7.060.9;
5.660.1, respectively; p,0.05; x2 6.695) and T12 (8.761.4;
7.661.7; 3.661.3, respectively; p,0.05; x2 6.593).
HOMA-IR (p,0.03), HOMA-b (p,0.002), QUICKI
(p,0.03), Matsuda indexes (p,0.002), fasting (p,0.05) and at
120 min glucose (p,0.01) were worse in GHD subjects at T0 than
in CS. No differences in metabolic parameters were shown
between CS and GHD at T12 (Table 1).
GHD before and after GH Discontinuation According to
GHR Genotype
By analysing the GHD group as a whole, we observed a huge
dispersion in INS and DI as mean6SD. Indeed, we addressed to
understand whether d3GHR has a role, according to some
literature suggestions (9,10). All the GHD subjects were analysed
for the GHR genotype, meanwhile 5 out of 40 CS withdrawn the
consent to perform this analysis.
Table 1. Clinical parameters of growth hormone deficient
(GHD, group 1) children at the end (T0) of rhGH therapy (T0),
after 12 months rhGH withdrawal (T12) and of control
subjects (CS, group 2).
GHD (group 1)
T0
GHD (group 1)
T12 CS (group 2)
Nu 23 23 40
M/F 12/11 12/11 22/18
IFG/IGT 1/2 0/0 0/0
Age (yr) 15.960.2 17.960.2 15.460.2
Weight (kg) 55.461.8 58.662.1 61.361.4
Centile weight 2362.1 2562.1 2761.5
Height (cm) 163.561.7a 166.161.2c 173.761.2a,c
SDS height 20.960.1a 2160.2c 1.160,1a,c
BMI (kg/m2) 20.960.5 21.260.5 20.460.2
HV (cm/yr) 1.560.4 1.060.1 –
Waist (cm) 72.861.2a 77.461.4 7960.8a
SBP (mmHg) 119.762.1b 119.463 124.461.3b
DBP (mmHg) 77.261.4 78.062.6 79.861.2
Abbreviations. BMI, body mass index; HV, height velocity; IFG, impaired fasting
glucose; IGT, impaired glucose tolerance; SBP: systolic blood pressure; DBP:
diastolic blood pressure, SDS: standard deviation score.
Data are expressed as mean6SEM. a: p,0.0001 GHD T0 vs CS; b: p,0.05 GHD
T0 vs CS; c: p,0.0001 GHD T12 vs CS.
doi:10.1371/journal.pone.0087157.t001
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The frequencies of the tree genotypes, d3/d3, fl/d3 and fl/fl
were respectively 9% [2], 35% [8], 56% [13] in GHD. Allele
frequencies were not different from those observed in the 35 CS
(Figure S1). Because frequency, the participants were therefore
divided into two groups, those homozygote for the fl/fl alleles (Del)
and those hetero- and homozygote for the deleted isoform
combined (nDel).
Del and nDel GHD had similar anthropometric and metabolic
parameters at T0 with exception of HDL-c which was higher in
Del GHD (56.561.9 vs 49.163.0 mg/dl, p,0.01).
At T6, Del GHD showed lower glucose levels at baseline and
after OGTT than nDel GHD (fasting glucose: 78.761.8 vs
87.562.9 mg/dl, p,0.01; T120 glucose: 90.764.6 vs
101.063.5 mg/dl, p,0.01; AUC 9703.06476.6 vs
12316.76447.7 mg/dl*h, p,0.01 and mean glucose
97.163.6 vs 118.562.8 mg/dl, p,0.0001). DI was higher in
Del than nDel GHD (10.461.0 vs 5.460.4; p,0.01) without
differences in INS, HOMA-IR and HOMA-b.
At T12, Del GHD showed lower glucose AUC
(9449.06552.4 vs 11771.061068.6 mg/dl*h; p,0.05) and
DG30–0 (29.564.5 vs 53.069.0 mg/dl; p,0.05), and higher
fasting insulin (9.060.8 vs 6.460.8 mUI/ml; p,0.05),HOMA-
IR (1.860.1 vs 1.360.2; p,0.05) and C-peptide (0.3960.09 vs
0.2460.03 ng/ml; p,0.04) than nDel GHD. Moreover, Del
GHD had INS (1.860.5 vs 0.760.1; p,0.01) and DI
(10.761.8 vs 5.061.0; p,0.01) higher than nDel GHD. nDel
GHD showed a progressively decrease from T0 to T12 in
HOMA-IR, HOMA-b, INS (p,0.05) and DI (not significant) with
stable C-peptide levels. Conversely, Del GHD showed a gradual
increase in DI (p,0.05), INS (not significant), and C-peptide
(0.2060.08 vs 0.3960.09; p,0.01) with a HOMA-IR decreasing
from T0 to T6 with a slight increase to T12 (p,0.01 for trend)
(Figure 1).
Del GHD presented stable higher HDL-c levels than nDel
GHD at any time point, whereas T-c, LDL-c and TG remained
similar. T-c levels decreased from T0 to T12 in nDel GHD
(141.067.4 at T0; 137.267.5 mg/dl at T6, 133.568.4 mg/dl at
T12; p,0.0001).
At T12, Del GHD presented lower fasting glucose (83.562.2 vs
88.062.2 mg/dl p,0.03), and higher fasting insulin (9.060.8 vs
6.860.6 mUI/ml; p,0.03), HOMA-b (167.7620.1 vs 96.9610.1;
p,0.003), and DI (10.761.8 vs 9.161.0 p,0.05) than Del CS.
Conversely, at T12 nDel GHD presented lower HOMA-IR
(1.360.2 vs 1.860.1 p,0.03), INS (0.760.1 vs 1.260.1 p,0.04),
and DI (5.061.0 vs 8.161.2 p,0.04) than nDel CS. Del and
nDel CS had higher C-peptide levels with respect to their GHD
counterpart (p,0.001).
Correlations
In GHD subjects during GH therapy, both INS and DI were
correlated with GH weekly dose (r: 20.399; p,0.05 and r:
20.529; p,0.01, respectively). Correlation was maintained when
Table 2. Glucometabolic parameters of growth hormone deficient (GHD, group 1) children at the end of rhGH therapy (T0) and 6
(T6) and 12 (T12) months after rhGH withdrawal.
T0 T6 T12 pfor trend
Fasting glucose (mg/dl) 83.661.7 84.561.8 84.161.8 NS
30-min plasma glucose (mg/dl) 145.565.7 138.365.4 127.265.9 ,0.05
2-h plasma glucose (mg/dl) 110.164.2 98.663 92.565 ,0.01
AUC Glucose 0-120 min 11592.46521 11273.46381 10691.86613 NS
Mean Glucose (mg/dl) 114.764.2 111.163 105.464.9 NS
DG30-0 59.964.8 53.264.9 42.965.5 ,0.05
Fasting insulin (mUI/ml) 10.561.1 860.7 7.760.6 ,0.05
30-min plasma insulin (mUI/ml) 99.4612 80.6611.6 59.869 ,0.01
2-h plasma insulin (mUI/ml) 59.666.8 40.965.4 34.264.8 ,0.01
AUC Insulin 0–120 min 7875.66915 6554.46864 4882.16591 ,0.01
Mean Insulin (mUI/ml) 6667.2 53.366.4 40.664.3 ,0.01
DI30-0 88.8611.2 72.5611 52.268.6 ,0.01
HOMA-IR 2.260.2 1.760.1 1.660.1 ,0.05
HOMA%b 205.2623.8 148.5615.9 148.3616.2 ,0.05
INS 1.660.2 1.360.1 1.260.2 ,0.05
DI 6.860.7 7.260.6 7.961.0 NS
C-peptide (ng/ml) 0.2160.05 0.1960.04 0.3660.05 P,0.01
T-c (mg/dl) 141.664.6 136.264.5 136.866.9 NS
HDL-c (mg/dl) 52.262.0 46.261.7 48.262.6 NS
LDL-c (mg/dl) 76.163.6 77.563.2 76.665.7 NS
TG (mg/dl) 60.764.1 62.766.2 59.265.3 NS
IGF-1 (ng/ml) 629.6638 356.8617 332.6625 ,0.0001
IGF-1 SDS 1.2160.19 -0.0160.06 -0.1560.17 ,0.0001
Abbreviations. DI, disposition index; INS, insulinogenic index; AUC, area under the curve; DG0-30: delta glucose;; DI0-30: delta insulin; HDL-c, HDL-cholesterol; LDL-c,
LDL-cholesterol; T-c, total-cholesterol; TG, triglycerides. Data are expressed as mean6SEM. The significance among the three measures (T0, T6 and T12) was calculated
by Friedman test.
doi:10.1371/journal.pone.0087157.t002
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correcting for IGF-1 (INS r: 20.392, p,0.05; DI r: 20.526,
p,0.01p,0.01) or IGF-SDS (INS r: 20.398, p,0.05; DI r:
20.531, p,0.01) which also weights for age and gender. No
correlations were recorded after GH discontinuation.
IGF-1 levels and IGF-SDS were correlated with HOMA-IR at
T6 (r: 0.518 and r: 0.514, p,0.01) and T12 (r: 0.518 and r: 0.518,
p,0.01), and also with QUICKY and Matsuda indexes at T6
(QUICKI, r: 20.495 and r: 20.476, p,0.03; Matsuda index,
20.443 and r: 0.302; p,0.05) and T12 (QUICKI, r: 20.611 and
r: 0.–609, p,0.02; Matsuda index, 20.543 and 20.359; p,0.05).
Discussion
A large number of studies have addressed the metabolic
consequences of adult GHD, in contrast studies investigating
glucose and insulin metabolism at the end of GH therapy in not
confirmed GHD adolescents during the transition phase are
lacking. The lack of published data reflects the clinical practice of
stopping the follow up in adolescents at the achievement of adult
height and with not confirmed GHD at reevaluation. This practice
makes a gap in the understanding of GH biology and of long-term
safety of rhGH treatment. In the present study, we observed that
after 1 year of rhGH withdrawal metabolic parameters are similar
between not confirmed GHD and matched control subjects.
Moreover, during GH treatment, higher insulin-resistance at
fasting and lower insulin-sensitivity during OGTT are associated
with higher HOMA-b and insulinogenic index and a stable DI in
the group as a whole. The d3GHR deletion may have a role on
the metabolic risk with a more pronounced reduction of HOMA-
IR and compensatory insulin secretion in nDel GHD, and with
lower glucose levels and a higher increase in DI and fasting C-
peptide in Del GHD at the end of the treatment.
First of all, we showed that whether glucose impairment and/or
insulin resistance occurred during the treatment with rhGH, these
are transient and quickly restored also in not confirmed GHD
adolescents, as already demonstrated in literature in adolescents
with persistent GHD [19,34]. Although puberty is ongoing, insulin
resistance at fasting and insulin sensitivity during OGTT
progressively return to similar levels to age, puberty, and weight
matched healthy adolescents. On the other hand, it is interesting
that GHD treated adolescents have the well-known higher insulin
resistance at fasting [35,36] but it is coupled with a compensatory
insulin secretion both at fasting, measured as HOMA-b, and
during OGTT, measured as INS with also a stable DI. Indexes of
insulin sensitivity (Matsuda index) and early insulin responses to
oral glucose (INS) that were derived from baseline and follow-up
OGTTs did not appear to be significant predictors for the
development of type 2 diabetes. In contrast, the baseline DI, which
significantly assesses beta-cell function in the context of insulin
sensitivity, predicts the risk of deteriorating glucose tolerance in
youths [30]. Thus, insulin secretion can be truly evaluated only in
relation to the degree of insulin sensitivity. Indeed, our data on DI
suggest that whether the treatment with GH has a detrimental role
on insulin resistance because it stimulates lipolysis, in youths
pancreas maintains a beta-cell compensatory capacity and is able
to answer to a relative hyperglycemia with a higher insulin
secretion which counterbalances the GH inhibited insulin-
stimulated glucose uptake in the muscles without impact on future
type 2 diabetes risk in those healthy [4,5]. Similarly, although M
values at euglycemic hyperinsulinemic clamp were higher after a
short rhGH withdrawal, in GHD treated young adults M values
Figure 1. HOMA-IR, Insulinogenic (INS) and disposition (DI) index in GH deficient (GHD, group 1) and healthy (CS, group 2)
adolescents with (Del, 27 subjects) and without (nDel, 31 subjects) the GH receptor (GHR) exon 3 deletion (d3GHR). GHD adolescents
are evaluated in the last year of therapy (T0) and after six (T6) and twelve (T12) rhGH withdrawal. Data are expressed as mean6SEM. The significance
among the three measures (T0, T6 and T12) was calculated by Friedman test. The significance between GHD and CS was calculated by Mann-Whitney
U test. *p,0.05.
doi:10.1371/journal.pone.0087157.g001
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were similar than matched controls [36]. Also in small for
gestational age GH treated adolescents, insulin sensitivity
decreased but DI remained stable at puberty [37]. We could
hypothesize that the preserved beta-cell function at early age
protects from type 2 diabetes and that when DI progressively
decreases with age and obesity a sustained glucose impairment
arises more likely as in adults. A direct role of GH on insulin
antagonism is supported by the negative correlation between GH
weekly dose and INS and DI, suggesting that the pancreas
compensation we observed is secondary to the peripheral
detrimental action of GH.
Studies conducted in adults and children suggest that insulin
resistance and glucose alteration are more frequent in GH treated
subjects with risk factors like age, obesity, an adverse metabolic
profile before therapy, syndromes or history of tumors [16].
Genomic profiles, like GHR polymorphisms could be inserted in
this list. The d3GHR deletion is the most investigated polymor-
phism of GHR in both healthy subjects and patients with GHD or
other diseases such as acromegaly or type 2 diabetes [38]. The
d3GHR variant consisting of genomic exon 3 deletion has been
linked with increased receptor activity due to an enhanced signal
transduction. Its biological role on glucose metabolism is still
controversial. Data derived by the Stockholm Diabetes Prevention
Program suggest the homozygosity for the d3GHR allele as
preventive of type 2 diabetes in adults. However, when other
factors cause overt type 2 diabetes, the d3GHR allele confers a
phenotype indicative of risk for metabolic disorders [10]. In
Chinese obese children fasting insulin, HOMA-IR, and lipid
profile were significantly lower in the homozygous and heterozy-
gous d3GHR group than in the full-length GHR group [39].
Moreover, the presence of at least one d3GHR allele was
associated with higher insulin secretion for a given degree of
insulin sensitivity and with a higher disposition index in healthy
normal weight children and adolescents during puberty in the
COPENHAGEN puberty study [11].
All these data are in agreement with our observation that
glucose levels are lower and DI, fasting C-peptide and nearly to
significance INS, were higher in Del GHD adolescents after
stopping therapy, suggesting that GHR exon 3 deletion gene
polymorphism may play a role in modulating insulin secretion to a
glucose challenge and peripheral insulin activity at least during
periods of high endogenous GH secretion like puberty. Higher
fasting C-peptide in subjects with at least one copy of the exon-3
deleted GHR than those with the full length one were also
demonstrated in adults [10]. However, the changes are apparent
after rhGH withdrawal in our population. This result is in line
with that of Giavoli et al. who recorded a higher prevalence of
impaired glucose tolerance after both 1 and 5 years of rhGH
therapy in GHD adults positive for the d3GHR [9]. The enhanced
activity of the d3GHR isoform may mediate the metabolic effects
of rhGH on glucose homeostasis. We can speculate that a more
pronounced GH activity has a strong lipolytic effect and insulin
antagonism. As a consequence, a worse glucose homeostasis in
adults and, more likely, a partial deterioration in peripheral insulin
activity, reflected by DI, in adolescents become apparent. This
hypothesis is fully in agreement with the fact that in healthy people
when other factors cause overt type 2 diabetes, the d3GHR allele
is not protective but confers a more impaired metabolic phenotype
[10]. Because normal adolescents with d3GHR have higher DI
during puberty and GHD unconfirmed subjects present an
increase in DI after rhGH withdrawal, a threshold for the
metabolic GH activity is suggested, in agreement with studies
which failed to record alterations in glucose metabolism for
treatments with rhGH very low doses [40].
GH plays an important role in the regulation of lipoprotein
metabolism. In patients with d3GHR we also observed higher
HDL-cholesterol levels during rhGH treatment and after rhGH
withdrawal. These findings are in line with data in healthy and
hypertensive adults [41] and support the idea that sequence
variations in the GHR may have important effects on metabolic
phenotype as a whole. Accordingly, other polymorphisms in the
GHR have been shown to modify HDL cholesterol concentration
also in hyperlipidaemic patients [42].
It has to note that our subjects progressively decreased IGF-I
levels after rhGH withdrawal but remained in the middle part of
the normal range. Higher IGF-I levels in the last year of rhGH
treatment were due to the treatment and, in absence of a
confirmed GHD during the transition phase, their levels quickly
restored in the middle of normality. Interestingly, insulin resistance
and sensitivity negatively correlated with them only after the
withdrawal of the therapy. This is adequate with previous study
that attest the U shape relation of IGF-I with the risk of diabetes is
evident in a healthy population when confounders are removed
[43].
There are limitations in the present study. First is that we did
not perform an intravenous glucose tolerance test (IVGTT). The
IVGTT is validated and more reproducible than the OGTT,
because independent by confounding factors as the incretin effect
is. However, the IVGTT only describes an experimental model
and is far to be used in clinical practice. We decided to use the
OGTT instead of IVGTT because OGTT describes the post-meal
dynamics which is of interest for the GH physiology being GH a
hormone that principally acts in the post-absorptive phase [1].
Moreover, we chose the OGTT-derived indices of insulin
sensitivity and secretion because they correlate well with clamp
measures in children [44,45], are easily calculated in epidemio-
logical or intervention studies, and DI calculated by the OGTT
has been demonstrated to predict diabetes development in adults
[24]. Furthermore, the OGTT is the test that is classically
performed in the clinical practice during rhGH treatment being
simpler and cheaper than IVGTT. Moreover, we did not evaluate
C-peptide during the test but only at fasting. The second limitation
is that we were unable to demonstrate a gene dosage effect with
respect to the d3GHR allele because the group of homozygous
subjects was too small to analyse them separately. A study in a
wider cohort could address this question. However, many
published studies on the d3GHR also in wider populations [9–
11] grouped together subjects bearing at least one copy of the
exon-3 deleted GHR according to the hypothesis of the dominant
model [46].
On the whole, in not confirmed GHD adolescents the fasting
deterioration in glucose homeostasis is efficaciously coupled with a
compensatory insulin secretion and activity for the degree of
insulin-sensitivity at glucose challenge also in puberty. In
adolescents during puberty, the presence of at least one d3GHR
allele, despite a slightly higher fasting insulin resistance, is
associated with lower glucose levels and higher HOMA-b, fasting
C-peptide, HDL-cholesterol and DI at OGTT after rhGH
withdrawal. Because a more pronounced activity of the d3GHR
isoform, a major risk to develop an impairment in glucose
homeostasis during the treatment could be hypothesized and
future studies should address this question. OGTT should be
routinely performed in clinical practice to better stratified GHD
subjects during the treatment. Screening for the d3GHR in GHD
treated subjects, also in childhood may help physicians to follow
and phenotype patients during the treatment.
Disposition Index in GHD Adolescents
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Supporting Information
Figure S1 Analysis of the GHR exon 3 polymorphism. a)
Schematic representation of the multiplex PCR assay used to
detect the GHR exon 3 polymorphism. One forward (G1) and two
reverse primers (G2 and G3) were used. Primers G1 and G3 (this
located within exon 3) are designed to detect the GHR-fl allele by
the amplification of a 935 bp fragment (the 3248 bp fragment is
non amplified under the conditions used); primers G1 and G2
allow the amplification of the GHR-d3 by producing a 532 bp
fragment. b) Genotyping of the GHR exon 3 polymorphism. The
presence of a 935 bp band indicates the genotypes homozygous
for GHR-fl (#1,2,3,6,8,10,11,12) the presence of a band of 532 bp
indicates the genotype homozygous for GHR-d3 (#4) and the
presence of both the bands indicates the herozygotes (#5,7,9,13).
A 100 bp ladder is used as a molecular weight marker. c)
Distribution of the genotype in GHD and control (CS) subjects.
Five out of 40 CS did not give the consent to perform the genetic
analysis.
(TIF)
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